Skip to content

Contact +44 (0) 20 7060 7474 email us

Clinical Trials

Infectious Immunology Test Reagents Clinical Trial Analysis

 

Publication Date July 2009
Publisher Global Markets Direct
Product Type
Pages 119
ISBN Number not applicable
Product Code GMD02903

Price

£660.00
approximately: $999 | €737

pdf

Buy Now

Order above formats by FAX

Order by Fax

Summary

Global Markets Direct's "Infectious Immunology Test Reagents Clinical Trials Analysis" is an essential source of data and information pertaining to product clinical trials being carried out by Infectious Immunology Test Reagents manufacturers, globally. The report provides exhaustive information on each clinical investigation study with coverage detailed coverage on the pipeline products these trials are being carried out for.

Scope

  • The report provides analysis and review of the key clinical trials being carried out globally and across key Infectious Immunology Test Reagents market categories - Virology,Bacteriology,Parasitology,Infectious Immunology Rapid Tests,Infectious Immunology Calibrators and Controls
  • The report covers information on each product being clinically tested with detailed coverage on the pipeline product profile, the indication it's being investigated for etc.
  • The report provides an in-depth analysis of the clinical trials with information on trial phase, trial 0status, trial acronym, purpose, inclusion and exclusion criteria, description, design, intervention, investigator information, primary and secondary end-points and trial results
  • The report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by Global Markets Direct's team of industry experts.

Reasons to Buy

  • Effectively plan your Mergers and Acquisitions and partnership strategies by identifying companies with the most promising pipeline.
  • Stay ahead of the information curve in the fast changing Infectious Immunology Test Reagents market.
  • Plan in-licensing and out-licensing opportunities through review of pipeline products and technologies.
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Proactively plan and execute your competitive strategies by identifying clinical trials status of the leading competitive products in pipeline.
  • Stay ahead of competition by understanding the changing competitive landscape in specific geographies.

Contents

  • 1 List of Tables
  • 1.2 List of Figures
  • 2 Infectious Immunology Test Reagents Clinical Trials
    • 2.1 Infectious Immunology Test Reagents Clinical Trial By Equipment Type
    • 2.2 Infectious Immunology Test Reagents Clinical Trials By Trial Phase and Trial Status
    • 2.3 Infectious Immunology Test Reagents Pipeline Products By Development Stage
    • 2.4 Infectious Immunology Test Reagents Pipeline Products By Therapy Area
    • 2.5 Infectious Immunology Test Reagents Pipeline Products By News Summary
    • 2.6 Infectious Immunology Test Reagents APTIMA HPV Assay
      • 2.6.1 APTIMA HPV Assay Pivotal US Clinical Trial
    • 2.7 Infectious Immunology Test Reagents Tuberculosis Assay
      • 2.7.1 Clinical Development Program Of A Test For Diagnosing Tuberculosis
    • 2.8 Infectious Immunology Test Reagents TB PATCH DIAGNOSTIC
      • 2.8.1 Study Results for TB Patch Diagnostic
    • 2.9 Infectious Immunology Test Reagents Clearview HIV tests
      • 2.9.1 Clinical Sensitivity of the Clearview COMPLETE HIV 1/2, PMA # BP050009 and the Clearview HIV 1/2 STAT-PAK, PMA #BP050010 in the 12 - 17 Year Old Pediatric Population
    • 2.10 Infectious Immunology Test Reagents Jaguar GBS assay
      • 2.10.1 Rapid Detection Of Group B Streptococcus Using A Bedside Microfluidics Device: Labor And Delivery Study
      • 2.10.2 Rapid Detection Of Group B Streptococcus Using A Bedside Microfluidics Device: 35-37 Week Study
    • 2.11 Infectious Immunology Test Reagents VHF detection test
      • 2.11.1 Trial On Rapid Tests for Hemorrhagic Viruses
    • 2.12 Infectious Immunology Test Reagents ID-Tag Respiratory Viral Panel
      • 2.12.1 Clinical Evaluation of the ID-TagTM RVP Test for Detection of Respiratory Viruses
    • 2.13 Infectious Immunology Test Reagents Triage Sepsis Panel
      • 2.13.1 Multi-Marker Index for the Risk Assessment of Sepsis in the Emergency Department
    • 2.14 Infectious Immunology Test Reagents fluID Rapid Influenza Test
      • 2.14.1 Comparison Of Fluid Rapid Influenza And BinaxNOW Influenza A & B
      • 2.14.2 CLINICAL STUDY PROTOCOL For The Prospective Evaluation Of The fluID Rapid Influenza Test
    • 2.15 Infectious Immunology Test Reagents Uni-Gold Legionella Urinary Antigen Test
      • 2.15.1 Evaluation Of Three Immunochromatographic Assays For Detection Of Legionella Pneumophila Serogroup 1 Antigen In Urine
      • 2.15.2 Evaluation Of A New Immunochromatographic Assay For The Detection Of Legionella Antigen In Non-concentrated And Concentrated Urine Samples
    • 2.16 Infectious Immunology Test Reagents VERSANT HIV-1 RNA 1.0 Assay (kPCR)
      • 2.16.1 To Evaluate The Analytical Performance Of The VERSANT HIV-1 RNA 1
      • 2.16.2 Assay (kPCR) And To Compare Assay Results With Quantitations From Other HIV-1 Viral Load Tests
    • 2.17 Infectious Immunology Test Reagents Seeplex Sepsis Multi-Pathogen Screening Test
      • 2.17.1 A Study On Rapid Sepsis Test Analyzes 68 Indicators For Deadly In-Hospital Disease
    • 2.18 Infectious Immunology Test Reagents Syntezza Detect-Ready MRSA Test
      • 2.18.1 Clinical Studies Conducted On Patient Samples Using The Syntezza Detect-Ready Mrsa Test And Two Leading Alternative qPCR-Based Diagnostic Assays
    • 2.19 Infectious Immunology Test Reagents ProParaflu+
      • 2.19.1 A Study On Accuracy Of Proflu+ Assay In A Multi-Site Clinical Study Comparing Results To Traditional Viral Culture
    • 2.20 Infectious Immunology Test Reagents MRSA/MSSA Blood Culture Test
      • 2.20.1 Primary Investigation Into the Performance of the MicroPhage S. Aureus / MSSA / MRSA Test Direct From Blood Culture
    • 2.21 Infectious Immunology Test Reagents Urine-based Diagnostic Assay
      • 2.21.1 The Matrix Metalloproteinase-9/Neutrophil Gelatinase-Associated Lipocalin Complex Plays A Role In Breast Tumor Growth And Is Present In The Urine Of Breast Cancer Patients
      • 2.21.2 Sample Collection Impacts The Performance Of Urinary Matrix Metalloproteinases (MMPs) As Diagnostic Biomarkers For Bladder Cancer Recurrence
      • 2.21.3 Increased Incidence Of Matrix Metalloproteinases In Urine Of Cancer Patients
      • 2.21.4 Molecular Profiling Of ADAM12 In Human Bladder Cancer
      • 2.21.5 A Study On ADAM 12 Cleaving Extracellular Matrix Proteins And Correlates With Cancer Status And Stage
      • 2.21.6 Phase 3 Study Of Bladder Cancer Recurrence Surveillance
    • 2.22 Infectious Immunology Test Reagents Multiplo Rapid HBV/HIV/HCV Antibody Test
      • 2.22.1 Single Use, Qualitative Immunoassay For The Detection Of Antibodies To The Hepatitis B Virus (HBV), Human Immunodeficiency Virus (HIV) And Hepatitis C Virus (HCV)
      • 2.22.2 Single Use, Qualitative Immunoassay For The Detection Of Antibodies To The Hepatitis B Virus (HBV), Human Immunodeficiency Virus (HIV) And Hepatitis C Virus (HCV)
  • 3 Recent Developments
    • 3.1 Product News
      • 3.1.1 Jun 12, 2009: Quest Diagnostics Launches HIV-1 Coreceptor Tropism Test
      • 3.1.2 Jun 09, 2009: DxNA Announces Submission Of Rapid Detection Platform Test For H1N1 To FDA
      • 3.1.3 Jun 03, 2009: Meridian Bioscience Announces FDA Approval For ImmunoCard STAT! CAMPY
      • 3.1.4 Jun 02, 2009: Warnex Introduces Test For Influenza A H1N1 Virus
      • 3.1.5 May 26, 2009: Roche Diagnostics Announces Launch Of LightCycler Mycobacterium Detection Kit For Tuberculosis Testing
      • 3.1.6 May 22, 2009: MicroPhage Presents Results Of New Diagnostic Test Platform At The 109th General Meeting Of The American Society Of Microbiology
      • 3.1.7 May 18, 2009: MicroPhage To Launch A Simple Diagnostic Assay For Rapid Identification Of skin And Soft Tissue Infections
      • 3.1.8 May 18, 2009: MicroPhage's Rapid Diagnostic Platform Demonstrates Feasibility In Skin And Soft Tissue Infections
      • 3.1.9 May 16, 2009: Mobidiag Announces Clinical Evaluation Results Of Its Prove-it Herpes Test And Also Develops A New Product, The Prove-it Bone And Joint Assay
      • 3.1.10 May 15, 2009: AdvanDx's GBS PNA FISH For Rapid Detection Of Group B Strep From Lim Broths Receives FDA Approval
      • 3.1.11 May 13, 2009: ViraCor Laboratories Announces Launch Of A New Ultrasensitive Molecular Test To Detect JC Virus
      • 3.1.12 May 11, 2009: Quest Diagnostics Launches Test For Identifying The H1N1 Swine Flu Virus
      • 3.1.13 May 07, 2009: Lyfetec's Influenza A/B Test Kit Tests Help Detect Possibility In Swine Flu Infected Patients
      • 3.1.14 Apr 30, 2009: Arrayit Corporation To Develop Rapid H1N1 Swine Flu Test Chip
      • 3.1.15 Apr 29, 2009: Seegene Launches Seeplex Diarrhea ACE Detection Test
      • 3.1.16 Apr 28, 2009: Prodesse, Inc Announces In Silico Testing Results Of ProFlu+ Assay
      • 3.1.17 Apr 28, 2009: QIAGEN Provides Screening Tests For Swine Flu Virus
      • 3.1.18 Apr 28, 2009: Response Biomedical Corporation Submits US FDA 510(k) For Market Clearance Of Rapid Respiratory Syncytial Virus Test
      • 3.1.19 Apr 27, 2009: Luminex Corporation Presents Interim Computer-Based Results On Sequence Analysis Of xTAG RVP And Swine Flu
      • 3.1.20 Apr 20, 2009: Seegene Announces Launch Of Seeplex Meningitis ACE Detection Test At 2009 Clinical Virology Symposium
      • 3.1.21 Apr 16, 2009: Prodesse, Inc. Receives FDA 510(k) Clearance To Market ProGastro Cd Assay For Detection Of Clostridium Difficile
      • 3.1.22 Apr 14, 2009: Prodesse Submits 510(k) Application To FDA For ProParaflu+ Assay
      • 3.1.23 Apr 07, 2009: Arbor Vita Corporation Announces US FDA Approval For AVantage A/H5N1 Flu Test
      • 3.1.24 Apr 01, 2009: Landmark Study Shows Significant Reduction In Death Rate From Cervical Cancer With The Digene HPV Test Compared To Other Methods Including Pap
      • 3.1.25 Mar 30, 2009: Inverness Medical Innovations Launches New FDA Cleared C. DIFF QUIK CHEK COMPLETE Rapid Test
      • 3.1.26 Mar 23, 2009: FDA Grants 510(k) Clearance To BD ProbeTec Qx Amplified Assays For The Detection Of Chlamydia And Neisseria
      • 3.1.27 Mar 18, 2009: Diagnostic HYBRIDS Gains FDA Approval For D3 DFA Metapneumovirus Identification Kit
      • 3.1.28 Mar 18, 2009: Phadia Announces US FDA Approval For Its ImmunoCAP Rapid POC Test
      • 3.1.29 Mar 13, 2009: Hologic Receives FDA Clearance For Cervista HPV HR And Cervista HPV 16/18 Tests
      • 3.1.30 Mar 06, 2009: QIAGEN Supports Cervical Cancer Screening For Underprivileged Chinese Women
      • 3.1.31 Mar 03, 2009: Seegene Announces The Launch Of Seeplex MTB ACE Detection Test
      • 3.1.32 Feb 24, 2009: BioTrove Announces Launch Of The OpenArray DLP Real-Time qPCR Platform
      • 3.1.33 Feb 10, 2009: AdvanDx's PNA FISH Test Helps Provide Best Care For OSF Saint Anthony Medical Center Patients With Bloodstream Infections
      • 3.1.34 Feb 10, 2009: Diagnostic Test Accuracy Of AIDS Is Influenced By Increasing Diversity Of HIV Strains
      • 3.1.35 Feb 09, 2009: Abbott Presents Clinical Data Of Antigen-Antibody Combo Test
      • 3.1.36 Feb 03, 2009: Prodesse Submits 510(k) Application To FDA For ProGastro Cd Assay
      • 3.1.37 Jan 30, 2009: US FDA Grants 510 (k) Clearance To AdvanDx's E. coli/P. aeruginosa PNA FISH Test
      • 3.1.38 Jan 28, 2009: OraSure Technologies Announces US FDA Approval For OraQuick ADVANCE 12-Month Shelf Life Dating
      • 3.1.39 Jan 15, 2009: ViraCor Laboratories Announces The Launch Of Fastest Available Cytomegalovirus Antiviral Resistance Test
      • 3.1.40 Jan 13, 2009: Microphage Inc Rapid MRSA Test Moves Closer To Market
      • 3.1.41 Jan 12, 2009: BD Diagnostics Receives FDA 510(k) Clearance For Novel Molecular Assay to Diagnose Clostridium Difficile Infections
      • 3.1.42 Jan 08, 2009: IntelligentMDx BK Viral Quantitative Assay Verification Studies Are Complete
      • 3.1.43 Dec 31, 2008: FDA Approves Most Comprehensive System To Test Donated Blood For HIV, Hepatitis B & Hepatitis C
      • 3.1.44 Dec 16, 2008: BioTrove Announces New OpenArray Platform Application To Identify Pediatric Respiratory Infectious Disease Agents
      • 3.1.45 Dec 16, 2008: Lab21 Expands Its Clinical Diagnostic Portfolio With FXG: RESP (Asp +) From Myconostica
      • 3.1.46 Dec 09, 2008: Health Canada Approves Respiratory Virus Multi-Pathogen Detection Tests
      • 3.1.47 Dec 03, 2008: Seegene Receives Approval From Health Canada For Its Respiratory Virus Multi-Pathogen Detection Tests
      • 3.1.48 Dec 02, 2008: Response Biomedical Corporation Announces Initiation Of Respiratory Syncytial Virus Infection Clinical Trial
      • 3.1.49 Nov 24, 2008: Cepheid Receives Health Canada License For First Molecular Diagnostic Test For MRSA And S. aureus Soft Tissue Infections
      • 3.1.50 Nov 05, 2008: OraSure Technologies To Sell OraQuick ADVANCE Rapid HIV-1/2 Antibody Test Directly To US Hospitals
      • 3.1.51 Oct 30, 2008: Response Biomedical Announces Launch Of RAMP Technology In 3M Rapid Detection Flu A+B Test At ICAAC/IDSA Conference
      • 3.1.52 Oct 28, 2008: OraSure Technologies Files For FDA Approval Of OraQuick Rapid Hepatitis C Test
      • 3.1.53 Oct 22, 2008: AdvanDx's PNA FISH Test Shown To Reduce Mortality By 42% For Patients With Hospital-Acquired Enterococcus Faecium Bloodstream Infections
      • 3.1.54 Oct 16, 2008: DHI Releases D3 Ultra 8 DFA Respiratory Virus Screening & ID Kit In Canada
      • 3.1.55 Oct 16, 2008: SIRS-Lab Receives ISO Certification For VYOO, Molecular In-Vitro Sepsis Diagnostics
      • 3.1.56 Oct 13, 2008: OraSure Technologies Helps Expand Access To Rapid HIV Testing In Recognition Of National Latino AIDS Awareness Day
      • 3.1.57 Oct 08, 2008: Luminex Corporation Receives Clearance From Health Canada For xTAG Respiratory Viral Panel
      • 3.1.58 Oct 01, 2008: Abbott Files PMA Application To FDA For Market Clearance Of ARCHITECT CORE
      • 3.1.59 Sep 29, 2008: Cepheid Receives FDA Clearance For First Rapid On-Demand Molecular Diagnostic Test For MRSA And S. Aureus
      • 3.1.60 Sep 25, 2008: SensiGen HPV Assay Enables Major Breakthrough In Diagnosis And Treatment Of Head And Neck Cancer
      • 3.1.61 Sep 24, 2008: QFT Shows Relationship Of Treatment Effectiveness In Active Pulmonary TB
      • 3.1.62 Sep 22, 2008: First Published Study Of New HPV Test For Developing Countries Shows High Accuracy In Predicting Cervical Disease
      • 3.1.63 Sep 05, 2008: FDA Approves Roche First Hepatitis B Viral Load Test
      • 3.1.64 Aug 13, 2008: FDA Grants Full Approval Of PROCLEIX ULTRIO Blood Screening Assay
      • 3.1.65 Aug 05, 2008: HX Diagnostics And Nanogen Expand Collaboration
      • 3.1.66 Aug 04, 2008: Monogram Biosciences (MGRM) Launches First Resistance Assay For HIV Integrase Inhibitors
      • 3.1.67 Jul 10, 2008: Zeus Scientific To Offer A Rapid Nasal Screening Test For Methicillin-Resistant Staphylococcus Aureus
      • 3.1.68 May 01, 2008: Prodesse Announces Clinical Trial Sites For ProGastro Cd
      • 3.1.69 Apr 17, 2008: Response Biomedical Receives US FDA 510(k) Market Clearance Of Rapid Influenza A+B Test
      • 3.1.70 Apr 08, 2008: Roche Diagnostics Expands Availability Of HCV Immunoassay
      • 3.1.71 Apr 08, 2008: Roche Diagnostics Expands Availability Of HCV Immunoassay
      • 3.1.72 Mar 12, 2008: ACON Laboratories, Inc Announces The Launch Of ToRCH EIA Test Kits
      • 3.1.73 Sep 11, 2007: Seegene Introduces A Diagnostic Test Kit For Detecting 18 Different Virus- And Bacteria-Born Respiratory Infections In A Single Tube
      • 3.1.74 Jun 11, 2007: Response Biomedical Files For US FDA 510(k) Market Clearance Of Rapid Influenza A+B Test
      • 3.1.75 May 24, 2007: FDA Approves Gen-Probe's Automated PROCLEIX TIGRIS System To Test Donated Blood With The PROCLEIX ULTRIO Assay
      • 3.1.76 May 23, 2007: MedMira Announces Russian Clearance For Its Multiplo Test
      • 3.1.77 Apr 26, 2007: Ability Of The BD ProbeTec ET System To Detect Variant Chlamydia trachomatis Is Confirmed
      • 3.1.78 Mar 08, 2007: FDA Accepts For Review New Roche Diagnostics Blood Screening Test
      • 3.1.79 Mar 07, 2006: New Test For Improved Detection Of HIV And Hepatitis Viruses In Donated Blood Receives CE Mark Certification
      • 3.1.80 Jul 03, 2003: Clinical Trial Site Using Roche's TaqScreen West Nile Virus Test Intercepts First Unit Of Infected Blood
    • 3.2 Product Approvals
      • 3.2.1 Jun 03, 2009: Meridian Bioscience Announces FDA Approval For ImmunoCard STAT! CAMPY
      • 3.2.2 May 15, 2009: AdvanDx's GBS PNA FISH For Rapid Detection Of Group B Strep From Lim Broths Receives FDA Approval
      • 3.2.3 Apr 16, 2009: Prodesse, Inc. Receives FDA 510(k) Clearance To Market ProGastro Cd Assay For Detection Of Clostridium Difficile
      • 3.2.4 Apr 07, 2009: Arbor Vita Corporation Announces US FDA Approval For AVantage A/H5N1 Flu Test
      • 3.2.5 Mar 23, 2009: FDA Grants 510(k) Clearance To BD ProbeTec Qx Amplified Assays For The Detection Of Chlamydia And Neisseria
      • 3.2.6 Mar 18, 2009: Diagnostic HYBRIDS Gains FDA Approval For D3 DFA Metapneumovirus Identification Kit
      • 3.2.7 Mar 18, 2009: Phadia Announces US FDA Approval For Its ImmunoCAP Rapid POC Test
      • 3.2.8 Mar 13, 2009: Hologic Receives FDA Clearance For Cervista HPV HR And Cervista HPV 16/18 Tests
      • 3.2.9 Jan 30, 2009: US FDA Grants 510 (k) Clearance To AdvanDx's E. coli/P. aeruginosa PNA FISH Test
      • 3.2.10 Jan 28, 2009: OraSure Technologies Announces US FDA Approval For OraQuick ADVANCE 12-Month Shelf Life Dating
      • 3.2.11 Jan 12, 2009: BD Diagnostics Receives FDA 510(k) Clearance For Novel Molecular Assay to Diagnose Clostridium Difficile Infections
      • 3.2.12 Dec 31, 2008: FDA Approves Most Comprehensive System To Test Donated Blood For HIV, Hepatitis B & Hepatitis C
      • 3.2.13 Dec 09, 2008: Health Canada Approves Respiratory Virus Multi-Pathogen Detection Tests
      • 3.2.14 Dec 03, 2008: Seegene Receives Approval From Health Canada For Its Respiratory Virus Multi-Pathogen Detection Tests
      • 3.2.15 Nov 24, 2008: Cepheid Receives Health Canada License For First Molecular Diagnostic Test For MRSA And S. aureus Soft Tissue Infections
      • 3.2.16 Oct 16, 2008: SIRS-Lab Receives ISO Certification For VYOO, Molecular In-Vitro Sepsis Diagnostics
      • 3.2.17 Oct 08, 2008: Luminex Corporation Receives Clearance From Health Canada For xTAG Respiratory Viral Panel
      • 3.2.18 Sep 29, 2008: Cepheid Receives FDA Clearance For First Rapid On-Demand Molecular Diagnostic Test For MRSA And S. Aureus
      • 3.2.19 Sep 05, 2008: FDA Approves Roche First Hepatitis B Viral Load Test
      • 3.2.20 Aug 13, 2008: FDA Grants Full Approval Of PROCLEIX ULTRIO Blood Screening Assay
    • 3.3 Clinical Trials
      • 3.3.1 May 22, 2009: MicroPhage Presents Results Of New Diagnostic Test Platform At The 109th General Meeting Of The American Society Of Microbiology
      • 3.3.2 May 18, 2009: MicroPhage's Rapid Diagnostic Platform Demonstrates Feasibility In Skin And Soft Tissue Infections
      • 3.3.3 May 16, 2009: Mobidiag Announces Clinical Evaluation Results Of Its Prove-it Herpes Test And Also Develops A New Product, The Prove-it Bone And Joint Assay
      • 3.3.4 Apr 28, 2009: Prodesse, Inc Announces In Silico Testing Results Of ProFlu+ Assay
      • 3.3.5 Apr 27, 2009: Luminex Corporation Presents Interim Computer-Based Results On Sequence Analysis Of xTAG RVP And Swine Flu
      • 3.3.6 Apr 01, 2009: Landmark Study Shows Significant Reduction In Death Rate From Cervical Cancer With The Digene HPV Test Compared To Other Methods Including Pap
      • 3.3.7 Feb 10, 2009: AdvanDx's PNA FISH Test Helps Provide Best Care For OSF Saint Anthony Medical Center Patients With Bloodstream Infections
      • 3.3.8 Feb 10, 2009: Diagnostic Test Accuracy Of AIDS Is Influenced By Increasing Diversity Of HIV Strains
      • 3.3.9 Feb 09, 2009: Abbott Presents Clinical Data Of Antigen-Antibody Combo Test
      • 3.3.10 Jan 13, 2009: Microphage Inc Rapid MRSA Test Moves Closer To Market
      • 3.3.11 Jan 08, 2009: IntelligentMDx BK Viral Quantitative Assay Verification Studies Are Complete
      • 3.3.12 Dec 16, 2008: BioTrove Announces New OpenArray Platform Application To Identify Pediatric Respiratory Infectious Disease Agents
      • 3.3.13 Dec 02, 2008: Response Biomedical Corporation Announces Initiation Of Respiratory Syncytial Virus Infection Clinical Trial
      • 3.3.14 Oct 22, 2008: AdvanDx's PNA FISH Test Shown To Reduce Mortality By 42% For Patients With Hospital-Acquired Enterococcus Faecium Bloodstream Infections
      • 3.3.15 Sep 25, 2008: SensiGen HPV Assay Enables Major Breakthrough In Diagnosis And Treatment Of Head And Neck Cancer
      • 3.3.16 Sep 24, 2008: QFT Shows Relationship Of Treatment Effectiveness In Active Pulmonary TB
      • 3.3.17 Sep 22, 2008: First Published Study Of New HPV Test For Developing Countries Shows High Accuracy In Predicting Cervical Disease
  • 4 Appendix
    • 4.1 Methodology
      • 4.1.1 Coverage
      • 4.1.2 Secondary Research
      • 4.1.3 Primary Research
      • 4.1.4 Expert Panel Validation
    • 4.2 Contact Us
    • 4.3 About Global Markets Direct
    • 4.4 Disclaimer
  • 1 List of Tables
    • Table 1: Infectious Immunology Test Reagents Clinical Trial By Equipment Type
    • Table 2: Infectious Immunology Test Reagents Clinical Trials By Trial Phase and Trial Status
    • Table 3: Infectious Immunology Test Reagents Pipeline Products By Development Stage
    • Table 4: Infectious Immunology Test Reagents Pipeline Products By Therapy Area
    • Table 5: Infectious Immunology Test Reagents Pipeline Products By News Summary
    • Table 6: APTIMA HPV Assay - APTIMA HPV Assay Pivotal US Clinical Trial
    • Table 7: Tuberculosis Assay - Clinical Development Program Of A Test For Diagnosing Tuberculosis
    • Table 8: TB PATCH DIAGNOSTIC - Study Results for TB Patch Diagnostic
    • Table 9: Clearview HIV tests - Clinical Sensitivity of the Clearview COMPLETE HIV 1/2, PMA # BP050009 and the Clearview HIV 1/2 STAT-PAK, PMA #BP050010 in the 12 - 17 Year Old Pediatric Population
    • Table 10: Jaguar GBS assay - Rapid Detection Of Group B Streptococcus Using A Bedside Microfluidics Device: Labor And Delivery Study
    • Table 11: Jaguar GBS assay - Rapid Detection Of Group B Streptococcus Using A Bedside Microfluidics Device: 35-37 Week Study
    • Table 12: VHF detection test - Trial On Rapid Tests for Hemorrhagic Viruses
    • Table 13: ID-Tag Respiratory Viral Panel - Clinical Evaluation of the ID-TagTM RVP Test for Detection of Respiratory Viruses
    • Table 14: Triage Sepsis Panel - Multi-Marker Index for the Risk Assessment of Sepsis in the Emergency Department
    • `Table 15: fluID Rapid Influenza Test - Comparison Of Fluid Rapid Influenza And BinaxNOW Influenza A & B
    • Table 16: fluID Rapid Influenza Test - CLINICAL STUDY PROTOCOL For The Prospective Evaluation Of The fluID Rapid Influenza Test
    • Table 17: Uni-Gold Legionella Urinary Antigen Test - Evaluation Of Three Immunochromatographic Assays For Detection Of Legionella Pneumophila Serogroup 1 Antigen In Urine
    • Table 18: Uni-Gold Legionella Urinary Antigen Test - Evaluation Of A New Immunochromatographic Assay For The Detection Of Legionella Antigen In Non-concentrated And Concentrated Urine Samples
    • Table 19: VERSANT HIV-1 RNA 1.0 Assay (kPCR) - To Evaluate The Analytical Performance Of The VERSANT HIV-1 RNA 1
    • Table 20: Seeplex Sepsis Multi-Pathogen Screening Test - A Study On Rapid Sepsis Test Analyzes 68 Indicators For Deadly In-Hospital Disease
    • Table 21: Syntezza Detect-Ready MRSA Test - Clinical Studies Conducted On Patient Samples Using The Syntezza Detect-Ready Mrsa Test And Two Leading Alternative qPCR-Based Diagnostic Assays
    • Table 22: ProParaflu+ - A Study On Accuracy Of Proflu+ Assay In A Multi-Site Clinical Study Comparing Results To Traditional Viral Culture
    • Table 23: MRSA/MSSA Blood Culture Test - Primary Investigation Into the Performance of the MicroPhage S. Aureus / MSSA / MRSA Test Direct From Blood Culture
    • Table 24: Urine-based Diagnostic Assay - The Matrix Metalloproteinase-9/Neutrophil Gelatinase-Associated Lipocalin Complex Plays A Role In Breast Tumor Growth And Is Present In The Urine Of Breast Cancer Patients
    • Table 25: Urine-based Diagnostic Assay - Sample Collection Impacts The Performance Of Urinary Matrix Metalloproteinases (MMPs) As Diagnostic Biomarkers For Bladder Cancer Recurrence
    • Table 26: Urine-based Diagnostic Assay - Increased Incidence Of Matrix Metalloproteinases In Urine Of Cancer Patients
    • Table 27: Urine-based Diagnostic Assay - Molecular Profiling Of ADAM12 In Human Bladder Cancer
    • Table 28: Urine-based Diagnostic Assay - A Study On ADAM 12 Cleaving Extracellular Matrix Proteins And Correlates With Cancer Status And Stage
    • Table 29: Urine-based Diagnostic Assay - Phase 3 Study Of Bladder Cancer Recurrence Surveillance
    • Table 30: Multiplo Rapid HBV/HIV/HCV Antibody Test - Single Use, Qualitative Immunoassay For The Detection Of Antibodies To The Hepatitis B Virus (HBV), Human Immunodeficiency Virus (HIV) And Hepatitis C Virus (HCV)
    • Table 31: Multiplo Rapid HBV/HIV/HCV Antibody Test - Single Use, Qualitative Immunoassay For The Detection Of Antibodies To The Hepatitis B Virus (HBV), Human Immunodeficiency Virus (HIV) And Hepatitis C Virus (HCV)
  • 1.2 List of Figures
    • Figure 1: Global Markets Direct Methodology